Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial
Event: ESC Congress 2025
Topic: Antidiabetic Pharmacotherapy
Session: What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
